This is the latest paper from Bredesen and colleagues, published in the Open Access Journal of Alzheimer’s Disease & Parkinsonism. When searching for the article, I found many websites sharing it, and this one has negative comments about Bredesen and his protocol, alongside some very positive ones! As always, with new approaches to diseases (or anything), there are many doubters, including doctors, other health care professionals, and patients themselves. Personally, I have found taking a holistic approach to dementia, that included dietary changes, lifestyle and other changes such as increasing exercise, as well as rehabilitation to have been very helpful in slowing the progression of the symptoms.
Even if this novel – and non pharmaceutical – approach to managing and even treating a disease group, where we are no closer to a cure or disease modifying drugs than we were ten years ago only improves quality of life and well being, it surely is worth investigating! Potentially, it also reduces a person risk of many other co morbidities such as cancer, hear disease and diabetes.
Bredesen DE, Sharlin K, Jenkins D, Okuno M, Youngberg W, et al. (2018) Reversal of Cognitive Decline: 100 Patients. J Alzheimers Dis Parkinsonism 8: 450.DOI: 10.4172/2161-0460.1000450
The first examples of reversal of cognitive decline in Alzheimer’s disease and the pre-Alzheimer’s disease conditions MCI (Mild Cognitive Impairment) and SCI (Subjective Cognitive Impairment) have recently been published. These two publications described a total of 19 patients showing sustained subjective and objective improvement in cognition, using a comprehensive, precision medicine approach that involves determining the potential contributors to the cognitive decline (e.g., activation of the innate immune system by pathogens or intestinal permeability, reduction in trophic or hormonal support, specific toxin exposure, or other contributors), using a computer-based algorithm to determine subtype and then addressing each contributor using a personalized, targeted, multi-factorial approach dubbed ReCODE for reversal of cognitive decline.
An obvious criticism of the initial studies is the small number of patients reported. Therefore, we report here 100 patients, treated by several different physicians, with documented improvement in cognition, in some cases with documentation of improvement in electrophysiology or imaging, as well. This additional report provides further support for a randomized, controlled clinical trial of the protocol and the overall approach.